Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eng3 Corporation is a Seattle-based biotechnology company that develops and manufactures the NanoVi device, a non-invasive technology designed to enhance cellular repair. The technology works by generating a specific electromagnetic signal that influences the structure of water to facilitate protein folding and mitigate damage caused by oxidative stress. NanoVi is widely utilized in sports medicine, anti-aging clinics, and by individuals seeking to improve recovery times and overall cellular health. The company's approach is unique in that it does not rely on supplements or drugs, but rather on biophysical signaling to support the body's natural regenerative processes. Eng3 serves a global market, providing solutions for both professional performance and general wellness.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Eng3.